Kidney disease treatment is undergoing a transformation, driven by exciting new research that reveals the protective power of semaglutide in patients with type 2 diabetes. Semaglutide, a medication ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity or ...

Please provide your email address to receive an email when new articles are posted on . More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A ...

A clinical trial has shown that Ozempic improves blood glucose levels and weight loss in overweight type 1 diabetics who use an automated insulin delivery system. It’s hoped that this will lead to the ...

Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity. In a ...

Semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease regardless of baseline adiposity. Cardiovascular benefit was largely ...

Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight ...

Semaglutide led to significant reductions in body weight, blood pressure, cholesterol, and HbA1c, but improvements were smaller than in clinical trials. Patients without diabetes experienced greater ...

Semaglutide shows promise in improving liver health and metabolic outcomes in MASH, enhancing steatohepatitis resolution and cardiometabolic measures. A large meta-analysis, published in Diabetology & ...

Semaglutide is a prescription medication. Injectable forms of the drug are available under the brand names Ozempic and Wegovy. The pill form of semaglutide is available as the brand-name drug Rybelsus ...